COVID-19 vaccination acceptance, safety and side-effects in European patients with severe asthma.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bossios Apostolos, Bacon Alison M, Eger Katrien, Paróczai Dóra, Schleich Florence, Hanon Shane, Sergejeva Svetlana, Zervas Eleftherios, Katsoulis Konstantinos, Aggelopoulou Christina, Kostikas Konstantinos, Gaki Eleni, Rovina Nikoletta, Csoma Zsuzsanna, Grisle Ineta, Bieksiené Kristina, Palacionyte Jolita, Ten Brinke Anneke, Hashimoto Simone, Mihălţan Florin, Nenasheva Natalia, Zvezdin Biljana, Čekerevac Ivan, Hromiš Sanja, Ćupurdija Vojislav, Lazic Zorica, Chaudhuri Rekha, Smith Steven James, Rupani Hitasha, Haitchi Hans Michael, Kurukulaaratchy Ramesh, Fulton Olivia, Frankemölle Betty, Howarth Peter, Porsbjerg Celeste, Bel Elisabeth H, Djukanovic Ratko, Hyland Michael E
Аннотация
METHODS: Questionnaires about vaccination beliefs (including the Vaccination Attitudes Examination (VAX) scale, a measure of vaccination hesitancy-related beliefs), vaccination side-effects, asthma control and overall safety perceptions following coronavirus disease 2019 (COVID-19) vaccination were sent to patients with severe asthma in 12 European countries between May and June 2021.
RESULTS: 660 participants returned completed questionnaires (87.4% response rate). Of these, 88% stated that they had been, or intended to be, vaccinated, 9.5% were undecided/hesitant and 3% had refused vaccination. Patients who hesitated or refused vaccination had more negative beliefs towards vaccination. Most patients reported mild (48.2%) or no side-effects (43.8%). Patients reporting severe side-effects (5.7%) had more negative beliefs. Most patients (88.8%) reported no change in asthma symptoms after vaccination, while 2.4% reported an improvement, 5.3% a slight deterioration and 1.2% a considerable deterioration. Almost all vaccinated (98%) patients would recommend vaccination to other severe asthma patients.
CONCLUSIONS: Uptake of vaccination in patients with severe asthma in Europe was high, with a small minority refusing vaccination. Beliefs predicted vaccination behaviour and side-effects. Vaccination had little impact on asthma control. Our findings in people with severe asthma support the broad message that COVID-19 vaccination is safe and well tolerated.